摘要
目的:评价进口与国产头孢哌酮/舒巴坦钠治疗下呼吸道感染的成本-效果。方法:对60例下呼吸道感染患者分别应用进口与国产头孢哌酮/舒巴坦钠(2∶1)进行治疗,观察疗效,并应用药物经济学成本-效果分析法进行评价。结果:2组成本分别为3164.00元、828.80元(P<0.05);有效率分别为83.3%、80.0%(P>0.05);成本-效果比分别为37.98、10.36;进口组相对于国产组的增量成本-效果比为707.64。结论:国产头孢哌酮/舒巴坦钠是更经济的选择。
OBJECTIVE： To evaluate the cost- effectiveness of imported and domestic cefoperazone/sulbactam sodium in treating lower respiratory infection. METHODS： 60 patients with lower respiratory infections were ascribed to receive imported or domestic cefoperazone/sulbactam sodium （2 ： 1） respectively, the curative effects of the drugs were monitored and evaluated by cost- effectiveness analysis. RESULTS： The costs of the two groups were 3 164.00yuan and 828.80yuan, respectively（P 〈 0.05） ;The effective rates were 83.3% and 80.0% （P 〉0.05）, respectively ;The cost- effectiveness ratios were 37.98 and 10.36, respectively ;And the incremental cost- effectiveness ratio of the imported group vs. the domestic group was 707.64. CONCLUSION： Domestic cefoperazone/sulbactam sodium is a more economical choice.
出处
《中国药房》
CAS
CSCD
北大核心
2006年第7期510-511,共2页
China Pharmacy
关键词
头孢哌酮/舒巴坦钠
进口
国产
下呼吸道感染
成本-效果分析
Cefoperazone/ sulbactam sodium
Imported
Domestic
Lower respiratory infection
Cost - effectiveness analysis
